Despite increase in the number of RCTs determining efficacy of probiotics for treating NAFLD, there is no uniformity in the parameters studied with a few exceptions like BMI and ALT. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.